Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 10, 2012 - Issue 6
Submit an article Journal homepage
50
Views
7
CrossRef citations to date
0
Altmetric
Editorial

Quercetin: bioflavonoids as part of interferon-free hepatitis C therapy?

Nu Lu Department of Hematology & Oncology, David Geffen School of Medicine at University of California, Los Angeles, CA, USA
,
Ronik Khachatoorian The Molecular Biology Institute, David Geffen School of Medicine at University of California, Los Angeles, CA, USA
&
Samuel W French Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California, Los Angeles, CA, USA and UCLA AIDS Institute, David Geffen School of Medicine at University of California, Los Angeles, CA, USA and Liver & Gastrointestinal Pathology, Department of Pathology & Laboratory Medicine, UCLA Center for Health Sciences, David Geffen School of Medicine at University of California, 10833 Le Conte Avenue, Los Angeles, CA 90095-91732, USA. [email protected]
Pages 619-621 | Published online: 10 Jan 2014

References

  • El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology127(5 Suppl. 1), S27–S34 (2004).
  • Alkhouri N, Zein NN. Protease inhibitors: silver bullets for chronic hepatitis C infection? Cleve. Clin. J. Med.79(3), 213–222 (2012).
  • Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology49(4), 1335–1374 (2009).
  • El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology36(5 Suppl. 1), S74–S83 (2002).
  • Fried MW, Afdhal NH, Wahed AS et al. A randomized, placebo-controlled trial of oral silymarin (milk thistle) for chronic hepatitis c: final results of the SYNCH multicenter study. Presented at: 62nd American Association for the Study of Liver Diseases Annual Meeting. San Francisco, CA, USA, 4–8 November 2011 (Abstract 228).
  • Bourliere M, Khaloun A, Wartelle-Bladou C et al. Future treatment of patients with HCV cirrhosis. Liver Int.32(Suppl. 1), 113–119 (2012).
  • Everson GT, Hoefs JC, Seeff LB et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology44(6), 1675–1684 (2006).
  • Gonzalez OFV, Raychaudhuri S, Loo R et al. The heat shock protein inhibitor quercetin attenuates hepatitis C virus production. Hepatology50(6), 1756–1764 (2009).
  • Sullivan CS, Pipas JM. The virus-chaperone connection. Virology287(1), 1–8 (2001).
  • French SW, Gonzalez O, Maloney E et al. The effects of bioflavonoids on hepatitis C viral infection and their therapeutic potential. FASEB J.25(1 Meeting Abstracts) (2011) (Abstract 366.310).
  • Khachatoorian R, Arumugaswami V, Ruchala P et al. A cell-permeable hairpin peptide inhibits hepatitis C viral nonstructural protein 5A-mediated translation and virus production. Hepatology doi:10.1002/hep.25533 (2011) (Epub ahead of print).
  • Jakubowicz-Gil J, Pawlikowska-Pawlega B, Piersiak T, Pawelec J, Gawron A. Quercetin suppresses heat shock-induced nuclear translocation of Hsp72. Folia Histochem. Cytobiol.43(3), 123–128 (2005).
  • Nieman D. Quercetins bioactive effects in human atheletes. Curr. Topics Nutraceut. Res.8(1), 33–44 (2010).
  • Nahmias Y, Goldwasser J, Casali M et al. Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology47(5), 1437–1445 (2008).
  • Bischoff SC. Quercetin: potentials in the prevention and therapy of disease. Curr. Opin. Clin. Nut. Metab. Care11(6), 733–740 (2008).
  • Brown JP. A review of the genetic effects of naturally occurring flavonoids, anthraquinones and related compounds. Mutat. Res.75(3), 243–277 (1980).
  • Harwood M, Danielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM, Lines TC. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem. Toxicol.45(11), 2179–2205 (2007).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.